The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Nicolas Penel
Research Funding - Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; DECIPHERA; Genmab; GlaxoSmithKline; MERSANA; MSD Oncology; OxOnc; Pfizer; PharmaMar; Roche; Tesaro
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Mersana; Mersana; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro
Research Funding - BMS; MSD Oncology
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; French National Cancer Institute (INCA)
 
Sophie Cousin
No Relationships to Disclose
 
Francois Bertucci
No Relationships to Disclose
 
Emmanuelle Bompas
No Relationships to Disclose
 
Jean-Christophe Eymard
No Relationships to Disclose
 
Esma Saada-Bouzid
No Relationships to Disclose
 
Patrick Soulie
Travel, Accommodations, Expenses - Ipsen; Pfizer; PharmaMar
 
Pascaline Boudou-Rouquette
Consulting or Advisory Role - Takeda; Takeda
Travel, Accommodations, Expenses - Takeda
 
Armelle Dufresne
No Relationships to Disclose
 
Axel Le Cesne
Honoraria - Bayer; PharmaMar
 
Olivier Mir
Stock and Other Ownership Interests - Amplitude Surgical; Ipsen; Transgene
Honoraria - Roche
Consulting or Advisory Role - Janssen; Lilly; Lundbeck; Pfizer; Roche
Speakers' Bureau - Lilly; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Ipsen
Travel, Accommodations, Expenses - Pfizer; Roche
 
Laetitia Gambotti
No Relationships to Disclose
 
Frédéric Legrand
No Relationships to Disclose
 
Clotilde Simon
No Relationships to Disclose
 
Assia Lamrani-Ghaouti
No Relationships to Disclose
 
Sylvie Chevret
No Relationships to Disclose
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Debiopharm Group; Faron Pharmaceuticals; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; ORION; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical